Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
US-2016143285-A1 · May 26, 2016 · US
US9585862B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9585862-B2 |
| Application number | US-201214118985-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 21, 2012 |
| Priority date | May 20, 2011 |
| Publication date | Mar 7, 2017 |
| Grant date | Mar 7, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property.
Opening claim text (preview).
What is claimed is: 1. A rivastigmine-containing patch, comprising: (a) a drug-containing adhesive layer comprising rivastigmine free base, a copolymer of butyl methacrylate and methyl methacrylate, and an adhesive; and (b) a layer for adhering to the skin comprising a silicon adhesive, wherein the adhesive in the drug-containing adhesive layer is a random copolymer of 58 to 66 parts by weight of 2-ethylhexyl acrylate, 28 to 36 parts by weight of methyl acrylate and 4 to 8 parts by weight of acrylic acid, and wherein the drug-containing adhesive layer and the layer for adhering to the skin do not contain tocopherol. 2. The rivastigmine-containing patch of claim 1 , wherein the adhesive in the drug-containing adhesive layer has a solids content of 36.5%, a Brookfield viscosity value of 8000 mPa·s, a density of 0.92 g/ml, and a solvent composition comprising 87% ethyl acetate and 13% hexane. 3. The rivastigmine-containing patch of claim 1 , wherein the copolymer of butyl methacrylate and methyl methacrylate is a random copolymer thereof, and has a weight average molecular weight of 130,000 g/mol to 170,000 g/mol. 4. The rivastigmine-containing patch of claim 3 , wherein the copolymer of butyl methacrylate and methyl methacrylate has a weight average molecular weight of about 150,000 g/mol. 5. The rivastigmine-containing patch of claim 1 , wherein the silicon adhesive is trimethylated silica treated with dimethyl siloxane. 6. The rivastigmine-containing patch of claim 5 , wherein the silicon adhesive has a viscosity of 1200 mPa·s, a solid content of 60%, and a peel adhesion value of 700 g/cm. 7. The rivastigmine-containing patch of claim 6 , wherein the silicon adhesive is used in an amount of 27 mg/10 cm 2 to 33 mg/10 cm 2 based on the dry weight of the layer for adhering to the skin. 8. A product comprising a rivastigmine-containing patch, wherein the rivastigmine-containing patch of claim 1 is packaged by nitrogen filling. 9. A product comprising a rivastigmine-containing patch, wherein the rivastigmine-containing patch of claim 3 is packaged by nitrogen filling. 10. A product comprising a rivastigmine-containing patch, wherein the rivastigmine-containing patch of claim 5 is packaged by nitrogen filling. 11. A product comprising a rivastigmine-containing patch, wherein the rivastigmine-containing patch of claim 7 is packaged by nitrogen filling. 12. The rivastigmine-containing patch of claim 1 , wherein the adhesive in the drug-containing adhesive layer has a solids content of 36.5%, a Brookfield viscosity value of 8000 mPa·s, a density of 0.92 g/ml, and a solvent composition comprising 87% ethyl acetate and 13% hexane, wherein the copolymer of butyl methacrylate and methyl methacrylate is a random copolymer thereof, and has a weight average molecular weight of 130,000 g/mol to 170,000 g/mol, and wherein the silicon adhesive is trimethylated silica treated with dimethyl siloxane. 13. The rivastigmine-containing patch of claim 12 , wherein the silicon adhesive has a viscosity of 1200 mPa·s, a solid content of 60%, and a peel adhesion value of 700 g/cm. 14. The rivastigmine-containing patch of claim 12 , wherein the silicon adhesive is used in an amount of 27 mg/10 cm 2 to 33 mg/10 cm 2 based on the dry weight of the layer for adhering to the skin.
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Adhesives · CPC title
of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title
Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145) · CPC title
Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.